In the same study, weight loss statistics showed reductions of 13.7% and 3.2% from baseline, with an estimated 10.5% greater weight loss with semaglutide. Some of the news isnt surprising: Obesity is a major risk factor for knee OA, and since semaglutide promotes weight loss by regulating appetite and blood sugar levels, its potential to reduce pressure on your knee joints is fairly well understood
By thoroughly understanding the patients medical history, carefully monitoring symptoms, considering drug interactions, creating individualized care plans, and maintaining open communication, providers can help ensure that semaglutide is used safely and effectively in asthma patients
PMCID: PMC6708115
With proper medical supervision, treatment is generally well tolerated and safe for long-term use
Symptoms: Dizziness, sweating, shakiness, confusion, and rapid heartbeat